Here are the latest winners of venture kick stage 1

11.02.2015

ObViz, Avrios, Onirigami and InterAx Biotech are the latest winners of venture kick’s first stage. The 4 newcomers in our program got kicked with CHF 10’000 of pre-seed capital. They are now getting ready to compete for CHF 20'000 more on the next stage.

ObViz-crm.jpg
The team of obViz
Avrios-crm.jpg
The team of Avrios
Onirigami-crm.jpg
The team of Onirigami
InterAx-Biotech-crm.jpg
The team of InterAx Biotech
ObViz (Opinion-based Visualization) is a news delivery platform coupled with a controversy-oriented social network. The EPFL based startup automatically displays the opposing viewpoints for a controversy, side by side. Their service empowers readers to comment and align themselves with their preferred side. It then recommends to users peers, with whom they can carry a meaningful conversation.

Avrios develops and markets business intelligence solutions for operators of commercial vehicles. The Avrios Business Intelligence Platform helps operators of commercial vehicles utilize their assets as efficiently as possible. Applying the latest research in machine learning, Avrios helps them automatically extract valuable and actionable business insights from the data they already have.

Onirigami is an adventure game with an innovative setup: An iPad and two connected figurines which are the heroes of the story. Each figurine is controlled by one of the two players. By moving the figurines on the screen, the players discover an interactive story. Watch Onirigami’s first prototype in a video here.

InterAx Biotech provides stabilized complexes for drug discovery. Over one third of all marketed drugs target G protein-coupled receptors. Dissection of drug-induced signaling requires understanding and access to complexes composed of receptor and signaling protein. These complexes are transient and dynamic in nature. The products of the Canton Aargau based startup are the missing tools necessary for comprehensive drug-induced signaling analysis contributing to qualified decisions before entering clinical trials.

Additional Links